New Results

The Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract

Yuejun Shi, Lei Shuai, Zhiyuan Wen, Chong Wang, Yuanyuan Yan, Zhe Jiao, Fenglin Guo, Zhen F. Fu, Huanchun Chen, Zhigao Bu, Guiqing Peng
doi: https://doi.org/10.1101/2020.11.12.380931

Abstract

The unprecedented coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a serious threat to global public health. Development of effective therapies against SARS-CoV-2 is urgently needed. Here, we evaluated the antiviral activity of a remdesivir parent nucleotide analog, GS441524, which targets the coronavirus RNA-dependent RNA polymerase enzyme, and a feline coronavirus prodrug, GC376, which targets its main protease, using a mouse-adapted SARS-CoV-2 infected mouse model. Our results showed that GS441524 effectively blocked the proliferation of SARS-CoV-2 in the mouse upper and lower respiratory tracts via combined intranasal (i.n.) and intramuscular (i.m.) treatment. However, the ability of high-dose GC376 (i.m. or i.n. and i.m.) was weaker than GS441524. Notably, low-dose combined application of GS441524 with GC376 could effectively protect mice against SARS-CoV-2 infection via i.n. or i.n. and i.m. treatment. Moreover, we found that the pharmacokinetic properties of GS441524 is better than GC376, and combined application of GC376 and GS441524 had a synergistic effect. Our findings support the further evaluation of the combined application of GC376 and GS441524 in future clinical studies.

Importance Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has seriously threatened global public health and economic development. Currently, effective therapies to treat COVID-19 are urgently needed. In this study, we assessed the efficacy of the preclinical inhibitors GC376 and GS441524 using a mouse-adapted SARS-CoV-2 infected mouse model for the first time. Our results showed that low-dose combined application of GC376 and GS441524 could effectively protect mice from HRB26M infection in the upper and lower respiratory tracts. Hence, the combined application should be developed and considered for future clinic practice.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which spread rapidly to more than 235 countries. The number of infections has exceeded 40 million, and more than 1 million deaths were reported (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). The World Health Organization (WHO) declared COVID-19 a global health emergency. Multiple vaccine candidates and therapeutics are in clinical trials (1–6), and effective treatments or cures for COVID-19 are still urgently needed.

Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses, and their genomic RNA is approximately 30 kb and contains at least 6 open reading frames (ORFs) (7). The first ORF (ORF 1a/b) encodes two polyproteins, pp1a and pp1ab, and these polyproteins are processed via a main protease (Mpro, also known as the 3C-like protease) and one or two papain-like proteases (PLPs) into 16 nonstructural proteins (nsps) (8, 9). These nsps engage in the production of subgenomic RNAs that encode four main structural proteins [envelope (E), membrane (M), spike (S), and nucleocapsid (N) proteins] and other accessory proteins (8, 9). Among these nsps, Mpro and nsp12 (RdRp) of SARS-CoV-2 are functionally and structurally conserved among these viruses and essential for viral replication; they are considered a potential target for the design of antiviral drugs (10–16).

GC376, a dipeptidyl bisulfite adduct salt, exerts strong inhibitory effects on picornaviruses and coronaviruses (11, 14, 15, 17). The latest research has shown that GC376 can also inhibit the replication of SARS-CoV-2 in Vero E6 cells (12, 13, 16). Moreover, antiviral treatment with GC376 led to a full recovery in laboratory cats with feline infectious peritonitis (FIP) caused by feline coronavirus (FIPV) (18). Currently, no studies have evaluated the ability of GC376 to inhibit SARS-CoV-2 in animals. In addition, remdesivir (RDV) and its parent nucleoside analog GS-441524 inhibit CoVs and other viruses (19–22). The latest research also suggests that RDV inhibits SARS-CoV-2 in vivo and in vitro (10, 23–27). However, recent research showed that RDV was not intended for lung-specific delivery, and GS-441524 is the predominant metabolite that reaches the lungs, which suggests that GS-441524 is superior to RDV for COVID-19 treatment (28, 29).

Because GC376 and GS441524 target the key proteases Mpro and RdRp of SARS-CoV-2 replication, respectively, their combined application may be more effective in the treatment of COVID-19. The combined application of GC376 with RDV produced additive sterilizing additive effects against SARS-CoV-2 in Vero E6 cells (13). However, the efficacy of the combined application of GC376 and GS441524 in the inhibition of SARS-CoV-2 replication was not investigated in vivo and in vitro. Our team generated a mouse-adapted SARS-CoV-2 (HRB26M) that efficiently replicates in the upper and lower respiratory tract in BALB/c mice (4, 30). Hence, we assessed the antiviral efficacy of GC376 and GS441524 in an HRB26M-infected BALB/c mouse model. Our results showed that GC376, which effectively inhibited the virus at the cellular level, was less effective in vivo. The ability of GS441524 to block the proliferation of SARS-CoV-2 was significantly higher than GC376 in mice. Notably, the low-dose combined application of GC376 and GS441524 could effectively block SARS-CoV-2 infection in the mouse upper and lower respiratory tract.

Results and Discussion

Structural analysis of GC376 and GS441524 targeting SARS-CoV-2 Mpro and nsp12 (RdRp)

In this study, we first analyzed the mechanism by which GC376 and GS441524 inhibit SARS-CoV-2 replication through structural biology methods. GC376 (Fig. 1a) is a preclinical inhibitor against feline infectious peritonitis virus (FIPV) (31) that has become a broad-spectrum prodrug targeting coronavirus Mpro (14, 32, 33). We determined the high-resolution crystal complex structure of Mpro with GC376 at a resolution of 2.35 Å (Table S1). The crystal of Mpro-GC376 belongs to the space group P1211, and an asymmetric unit contains two molecules (designated protomer A and protomer B) (Fig. 1b). The structure of each protomer contains three domains with the substrate-binding site comprised of a His41-Cys145 dyad located in the cleft between domain I and II (Supplementary Fig. 1). The electron density map clearly showed compound GC376 in the substrate binding pocket of the SARS-CoV-2 Mpro, and details of the interaction are shown in Fig. 1c and Supplementary Fig. 1. GC376 interacts with His41, Phe140, Leu141, Asn142, Ser144, Cys145, His163, His164, Met165, Glu166, His172, Asp187, Arg188 and Gln189 through many hydrogen bonds and hydrophobic interactions, and binds stably in the groove formed by domain I and domain II. Moreover, we found that GC376 is covalently attached to Cys145 as a hemithioacetal (Fig. 1c), which prevents the binding and processing of Mpro to the substrate (12, 16, 32). Additionally, GS441524 is the parent nucleoside of RDV (Fig. 1d and Supplementary Fig. 2a), and has shown broad-spectrum inhibition of the replication of various coronaviruses, including SARS-CoV-2 (28, 34, 35). Since the mechanism by which GS441524 inhibits SARS-CoV-2 replication is similar to that of RDV (28, 34), we showed the cryo-electron microscopy (cryo-EM) ternary structure of the complex with RDV (PDB: 7BV2) (10). Previous studies have shown that RDV, like many nucleotide analog prodrugs, inhibits viral RdRp activity through nonobligate RNA chain termination (10, 36, 37). Moreover, we observed that RDV stably bound nsp12 through hydrophobic interactions with Arg555, Asp623, Ser682, Thr687 and Asp760 (Fig. 1e, f and Supplementary Fig. 2b).

Fig.1
Fig.1 Structural analysis of GC-376 and GS441524 targeting SARS-CoV-2 Mpro and RdRp.

(a) The dipeptidyl protease inhibitor, GC376. (b) Crystal structure of SARS-CoV-2 Mpro in complex with GC376. (c) GC376 interacts covalently with the active cysteine site of SARS-CoV-2 Mpro. Electron density at 1.5 σ is shown in gray mesh. Hydrogen bonds are shown as red dashed lines. (d) The chemical structure of GS-441524. (e) Cryo-EM structure of the apo nsp12-nsp-7-nsp8 RdRp complex (PDB ID: 7BV2). (f) Enlarged view of the active site, depicting the interaction between RDV and surrounding amino acids.

Combined application of GC376 and GS441524 has an enhanced ability to inhibit SARS-CoV-2 in Vero E6 cells

We evaluated the inhibitory efficacy of GC376, GS441524 and the combined application of GC376 and GS441524 (molar ratio: 1:1) (GC376+GS441524) on the replication of live virus (SARS-CoV-2: HRB26 and HRB26M) in Vero E6 cells. We first tested the cellular cytotoxicity of these compounds in vitro. GC376 and GS441524 did not produce obvious cytotoxicity at concentrations up to 250 μM in Vero E6 cells (CC50 > 250 μM; Supplementary Fig. 3). Our results showed that GC376 and GS441524 were efficacious against HRB26, with 50% inhibitory concentration (EC50) values of 0.643±0.085 μM and 5.188±2.476 μM, respectively (Fig. 2a, b). GC376 and GS441524 were also efficacious against HRB26M, with EC50 values of 0.881±0.109 μM and 5.047±2.116 μM, respectively (Fig. 2d, e). Our results showed that the ability of GC376 to inhibit viral (HRB26 and HRB26M) replication was better than GS441524 when the agents were applied alone. We observed that the GC376+GS441524 more effectively inhibited HRB26 and HRB26M replication than single treatment, with EC50 values of 0.531±0.162 μM and 0.369±0.068 μM, respectively (Fig. 2c, f). In the replication process of coronavirus, Mpro is one of the first nsps processed by the polyprotein, and other replication-related proteins, such as RdRp, can be produced with the participation of Mpro and PLP proteases (8, 9). This phenomenon may be the reason why GC376 is better than GS441524, and their combined application may result in a synergistic effect because these agents target different proteins involved in virus replication.

Fig.2
Fig.2 GC376 and GS441524 potently inhibit SARS-CoV-2 in Vero E6 cells.

(a-c) Percent inhibition of SARS-CoV-2 (HRB26) by GC376, GS441524 and GC376+GS441524 in Vero E6 cells. (d-f) Percent inhibition of SARS-CoV-2 (HRB26M) by GC376, GS441524 and GC376+GS441524 in Vero E6 cells. The concentrations of GC376 and GS441524 ranged from 0 to 10 μM. The 50% inhibitory concentration (EC50) was calculated using GraphPad Prism 7.0 to assess inhibition ratios at different inhibitor concentrations. The error bars show the S.D. of the results from three replicates.

Low-dose GC376+GS441524 could effectively protect mice from HRB26M infection in the upper and lower respiratory tracts

The potential toxicity of GC376, GS441524 and GC376+GS441524 were evaluated in healthy specific pathogen-free (SPF) mice at 4-6 weeks. The mice were intramuscularly (i.m.) administered GC376 (40 mM/l, 100 μl), GS441524 (40 mM/l, 100 μl) and GC376+GS441524 (20 mM/l, 100 μl) for 15 days, and they were observed daily for adverse effects. During the study period, there were no clinically significant changes in vital signs or clinical laboratory parameters (Supplementary Fig. 4), indicating that the dose and administration route of GC376, GS441524 and GC376+GS441524 were suitable for the in vivo efficacy study.

We assessed the antiviral efficacy of i.m. administered GC376 (40 or 8 mM/l, 100 μl), GS441524 (40 or 8 mM/l, 100 μl) and GC376+GS441524 (20 or 4 mM/l, 100 μl) against SARS-CoV-2 in mice. In the compound-treated group, the viral RNA and viral titer were detected in the nasal turbinates and lungs on days 3 and 5 post-inoculation (p.i.); the viral RNA loads and viral titer in the nasal turbinates were not significantly decreased compared with those in the mock-treated mice on day 3 p.i (Fig. 3a, b and Supplementary Fig. 5a, b). Although no significant decreases in viral RNA loads were observed, high-dose GC376+GS441524 significantly inhibited the replication of SARS-CoV-2 in the turbinate on day 5 p.i. (Fig. 3c, d and Supplementary Fig. 5c, d). Our results showed that high-dose GS441524 and GC376+GS441524 completely inhibited the proliferation of SARS-CoV-2 in mouse lungs on days 3 and 5 p.i. (Fig. 3e f, g, h and Supplementary Fig. 6). Besides, the virus yields in the lungs of the high-dose GC376-treated group were significantly reduced compared to mock-treated mice on day 5 p.i., but it could not completely block the viral proliferation (Fig. 3h and Supplementary Fig. 6d). Additionally, the ability of the low-dose compound-treated group to inhibit viral replication was lower than the high-dose group in the lungs (Fig. 3e, f, g, h and Supplementary Fig. 6). Similar to RDV (30), high-dose GS441524 and GC376+GS441524 completely blocked the proliferation of SARS-CoV-2 in mouse lungs, but these agents failed to block virus proliferation in the upper respiratory turbinate on day 5 p.i. These data indicated that high-dose i.m. compound treatment (excluding GC376) efficiently inhibited the replication of SARS-CoV-2 in the lungs, but not in the nasal turbinates of BALB/c mice.

Fig.3
Fig.3 Evaluation of i.m. GC376, GS441524 and GC376+GS441524 against SARS-CoV-2 infection in mice.

Four- to six-week-old female BALB/c mice were intramuscularly administered a loading dose of GC376 (4 or 0.8 μM), GS441524 (4 or 0.8 μM), GC376+GS441524 (2 μM+2 μM or 0.4 μM+0.4 μM), followed by a corresponding daily maintenance dose. Control mice were administered vehicle solution (12% sulfobutylether-β- cyclodextrin, pH 3.5) daily, in parallel (0 μM). One hour after administration of the loading dose of GC376, GS441524, GC376+GS441524 or vehicle solution, the mice were inoculated intranasally with 103.6 PFU of HRB26M in a volume of 50 μl. On days 3 and 5 p.i., three mice in each group were euthanized and their nasal turbinates and lungs were collected. The viral RNA copies and infectious titers in the nasal turbinates (a-d) and lungs (e-h) were detected by qPCR and viral titration. The concentrations of the daily maintenance doses are shown.

Furthermore, we assessed whether intranasal (i.n.) administration would improve the efficacy of GC376 and GS441524 to inhibit the replication of SARS-CoV-2 in the upper respiratory tract. Mice were treated with GC376 (i.n. and i.n.+i.m.), GS441524 (i.n. and i.n.+i.m.) and GC376+GS441524 (i.n. and i.n.+i.m.). Our results showed that GS441524 and GC376+GS441524 markedly inhibited viral replication in nasal turbinates on days 3 and 5 p.i. (Fig. 4b, d and Supplementary Fig. 7b, d). Only slightly infectious virus was detected on day 5 p.i., although viral RNA was detected in 2 of the 3 mice in the GS441524-treated group (Fig. 4c, d and Supplementary Fig. 7c, d). However, i.n. administration of GS441524 did not significantly inhibit viral replication in the lungs compared to that of the mock-treated group on day 5 p.i (Fig. 4g, h and Supplementary Fig. 8c, d). Notably, we observed that i.n. administration of GC376+GS441524 blocked viral replication in the lungs on day 5 p.i., although viral RNA was detected in 1 of the 3 mice (Fig. 4 g, h and Supplementary Fig. 8 c, d). GS441524 treatment via i.n. and i.m. routes completely blocked viral replication in the nasal turbinates and lungs, although viral RNAs were detected from the nasal turbinates of 2 of the 3 mice on day 3 p.i (reduced approximately 700-fold compared to that of the mock-treated group) (Fig. 4 and Supplementary Figs. 7 and 8). Similarly, low-dose GC376+GS441524 treatment (i.n.+ i.m.) also completely blocked viral replication in the nasal turbinates and lungs, although viral RNAs were detected from the nasal turbinates of 2 of the 3 mice on day 3 p.i. and 5 p.i. (reduced approximately 1500-fold and 263-fold compared to that of the mock-treated group, respectively) (Fig. 4 and Supplementary Figs. 7 and 8). Although GC376 treatment via the i.n. or combined i.n. and i.m. routes reduced the level of virus replication on day 5 p.i (Supplementary Figs. 7d and 8d), it did not completely blocked viral replication in nasal turbinates and lungs (Fig. 4).

Fig.4
Fig.4 Evaluation of i.n. and i.m. GC376, GS441524 and GC376+GS441524 against SARS-CoV-2 infection in mice.

Four- to six-week-old female BALB/c mice were administered a loading dose of GC376 (1 μM, i.n. or 1 μM, i.n.+4 μM, i.m.), GS441524 (1 μM, i.n. or 1 μM, i.n.+4 μM, i.m.), GC376 + GS441524 (0.5 μM+0.5 μM, i.n. or 0.5 μM+0.5 μM, i.n. and 2 μM+2 μM, i.m.), followed by a corresponding daily maintenance dose. Control mice were administered vehicle solution (12% sulfobutylether-β- cyclodextrin, pH 3.5) daily in parallel (0 μM). One hour after administration of the loading dose of GC376, GS441524, GC376 + GS441524 or vehicle solution, the mice were inoculated intranasally with 103.6 PFU of HRB26M in a volume of 50 μl. On days 3 and 5 p.i., three mice in each group were euthanized and their nasal turbinates and lungs were collected. The viral RNA copies and infectious titers in the nasal turbinates (a-d) and lungs (e-h) were detected by qPCR and viral titration. The concentrations of the daily maintenance doses are shown.

Pharmacokinetics study of GC376 and GS441524 alone or in combination

To further examine the potential of GC376 and GS441524, we evaluated their pharmacokinetic (PK) properties in SPF SD rats following i.m. administration of GC376 (111 mg/kg), GS441524 (67 mg/kg) and GC376+GS441524 (55.5+33.5 mg/kg), which are the same doses used in mice according to weight. The PK results showed that GC376 and GS441524 were rapidly absorbed after i.m. administration, and the peak plasma level was reached 1.30±0.60 h and 2.00±1.10 h after injection, respectively (Fig. 5 and Table 1). Our results are consistent with the previously reported Tmax of GS441524 in patients (29) and GC376 in cats (18). We found that the maximum detected plasma drug concentration (Cmax) of GC376 (12.56±1.90 μg/ml) was approximately 2.5-fold lower than GS441524 (30.96±8.40 μg/ml) (Table 1). The value of the area under the curve (AUC0-t) of GS441524 (AUC0-t=183.33±64.36) was approximately 2.0-fold higher than GC376 (AUC0-t=92.14±9.99). However, the i.m. administered dose of GC376 was approximately 1.7-fold that of GS441524. We observed that the clearance rate of GC376 (CL/F, 1208±122 ml/h/kg) in plasma was approximately 2.9-fold that of GS441524 (CL/F, 423±186 ml/h/kg) (Table 1). These results indicated that the utilization efficiency of GS441524 in vivo is significantly higher than that of GC376. This finding may be one of the reasons for the poor ability of GC376 to inhibit SARS-CV-2 in vivo. In addition, current research has shown that GC376 can effectively eliminate FIPV in cats (18). However, this drug could not effectively inhibit SARS-CoV-2 in the upper and lower respiratory tracts in mice. One possible explanation is that GC376 may have difficulty reaching the mouse nasal turbinates and lungs, and the specific mechanism needs further study.

Fig.5
Fig.5 Plasma concentration-vs-time profiles following GC376, GS441524 and GC376+GS441524 administration in SD rats.

In the single-dose PK study, five SPF SD rats were i.m. injected with GC376 (111 mg/kg), GS441524 (67 mg/kg) and GC376+GS441524 (55.5+33.5 mg/kg) for the determination of serial plasma drug concentrations. Data were analyzed via GraphPad Prism7.0, and the error bars show the SEM of the results from five replicates.

View this table:
Table 1 Preliminary pharmacokinetic (PK) evaluation of compounds GC376 and GS441524 in SD rats.a

Furthermore, we found that the combined application of GC376 and GS441524 had a synergistic effect and extended T1/2 from 3.80±1.17 h to 5.13±2.56 h, Tmax from 2.00±1.10 h to 3.40±1.20 h and the residence time of GS441524 (MRT0-t from 4.50±1.11 h to 6.03±1.37 h) (Fig. 5c and Table 1). However, the injection dose was halved because the clearance rate was not changed, and the MRT0-t of GC376 decreased from 5.80±0.74 h to 2.97±0.41 h. The PK study results showed that GC376 reached Cmax earlier (Tmax=1.40±0.49) than GS441524 (Tmax=3.40±1.20 h) to produce a synergistic effect (Fig. 5c). When these agents were combined, GC376 was the first drug to inhibit SARS-CoV-2 replication. After the plasma concentration of GC376 decreased, GS441524 reached its Cmax (Fig. 5c and Table1) to produce a continuous inhibition of SARS-CoV-2 proliferation and maintain the effective concentration for a longer time. This phenomenon may explain why the combined application of GC376 and GS441524 was better than single application alone. In addition, the difference in the pharmacokinetics of GC376 and GS441524 between the upper and lower respiratory tract needs to be further evaluated.

In summary, we assessed the efficacy of GC376 and GS441524 to inhibit SARS-CoV-2 replication using a mouse-adapted virus infection model. Importantly, we found that intranasal administration of GS441524 and GC376+GS441524 significantly prevents the replication of virus in the upper respiratory tract, and the efficacy of GC376+GS441524 to inhibit the viral replication in the lower respiratory tract significantly better than that of GS441524. Combined i.n. and i.m. administration of GS441524 and GC376+GS441524 effectively protected mice against HRB26M infection in the upper and lower respiratory tracts, but GC376 alone failed to block the proliferation of SARS-CoV-2 in mice. Compared with GC376 and GS441524 alone, the dosage of GC376+GS441524 is halved, these results showed an additive effect of the combined application of the Mpro and RdRp inhibitors, so it should be developed and considered for future clinic practice.

Materials and methods

Compounds, cells, viruses and animal experiments

The compounds GC376 (molecular weight: 507.53 g/M) and GS441524 (molecular weight: 291.26 g/M) were synthesized at WuXi AppTec with purities higher than 95%. They were dissolved in 5% ethanol, 30% propylene glycol, 45% PEG 400, and 20% water with a concentration of 40 mM/l according to a previously described study (35).

Vero E6 cells (African green monkey kidney, ATCC) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Scientific, USA) containing 10% fetal bovine serum (Thermo Scientific, USA) and antibiotics, and incubated at 37°C with 5% CO2 (4). In addition, SARS-CoV-2/HRB26/human/2020/CHN (HRB26, GISAID access no. EPI_ISL_459909) and Mouse-adapted SARS-CoV-2/HRB26/human/2020/CHN (HRB26M, GISAID access no. EPI_ISL_459910) were obtained following the previous method (30). Infectious virus titers were determined using a plaque forming unit (PFU) assay in Vero E6 cells, and virus stocks were stored in aliquots at −80 °C until use.

Specific pathogen-free female BALB/c mice, aged 4-6 weeks were obtained from Beijing Vital River Laboratory Animal Technologies Co., Ltd (Beijing, China) and were housed and bred in the temperature-, humidity- and light cycle-controlled animal facility (20 ± 2 °C; 50 ± 10%; light, 7:00–19:00; dark, 19:00–7:00, respectively) of the Animal Center, Academy of Military Medical Sciences, Beijing.

Protein expression and purification

SARS-CoV-2 Mpro flanked by an N-terminal His6 tag was cloned into pET-32a (+). For expression of SARS-CoV-2 Mpro, the saved cells (from Sheng-ce Tao lab) were cultured at 37°C in LB medium containing 50 μg/ml ampicillin. Protein expression was induced with 0.8 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when the culture density reached an OD600 of 0.8, and cell growth continued for an additional 16 h at 18°C. Protein purification was performed as described previously (38, 39). Briefly, the cell supernatant was filtered with a 0.45-μm filter and loaded onto a nickel-charged HisTrap HP column (GE Healthcare). Proteins were eluted with elution buffer (20 mM Tris-HCl, 500 mM NaCl and 500 mM imidazole, pH 7.4). Then, the harvested protein was concentrated to approximately 2.0 ml and filtered using a Superdex 200 gel filtration column (GE Healthcare) equilibrated with buffer (20 mM Tris-HCl and 200 mM NaCl, pH 7.4). For crystallization, the purified protein was concentrated to approximately 8 mg/ml, flash frozen with liquid nitrogen, and stored at −80°C. The concentration of purified SARS-CoV-2 Mpro was determined by the absorbance at 280 nm (A280) using a NanoDrop 2000c UV-Vis spectrophotometer (Thermo Fisher Scientific).

Crystallization, data collection and structure determination

GC376 and Mpro (8 mg/ml) were incubated at room temperature for 1 h (molar ratio: 1:2), and the complex was crystallized by the hanging drop vapor diffusion method at 20°C. The best crystallization conditions for the complex were in hanging drops consisting of 2 μl of reservoir solution (0.1 M sodium malonate pH 6.0, 12% w/v polyethylene glycol 3,350) and 2 μl of the complex in 20 mM Tris-HCl and 200 mM NaCl, pH 7.4, followed by incubation at 20°C for 3 days. Then, the crystals were flash-cooled in liquid nitrogen in a cryoprotectant solution containing 30% ethylene glycol and 70% reservoir solution (0.1 M sodium malonate pH 6.0, 14% w/v polyethylene glycol 3,350). Data collection was performed at the research associates at Center for Protein Research (CPR), Huazhong Agricultural University (wavelength = 1.5418 Å, temperature = 100 K). Reflections were integrated, merged, and scaled using HKL-3000 (40), and the resulting statistics are listed in Table S1. The structure was solved by molecular replacement with PHASER (Phenix, Berkeley, CA, USA) (41) using the structure of the SARS-CoV-2 Mpro (PDB identifier 7BQY) as a starting model. Manual model rebuilding and refinement were performed using COOT (42) and the PHENIX software suite. Structural figures were generated using PyMOL (Schrödinger). Detailed molecular interactions were determined using LIGPLOT (43).

Evaluation of antiviral activity in Vero E6 cells

Cell viability was determined using the Cell Titer-Glo kit (Promega, Madison, WI, USA) following the manufacturer’s instructions. Briefly, Vero E6 cells were seeded in 96-well plates with opaque walls. After 12 to 16 h, the indicated concentrations of GC376 (0, 1, 5, 10, 50, 100, 500 μM), GS441524 (0, 1, 5, 10, 50, 100, 500 μM) and GC376+GS441524 (0, 0.5, 2.5, 5, 25, 50, 250μM) were added for 24h. Cell Titer-Glo reagent was added to each well, and luminescence was measured using a GloMax 96 Microplate Luminometer (Promega, Madison, WI, USA).

Antiviral activity experiment was determined following a previous method (30). Briefly, Vero E6 cells were pretreated with the indicated concentrations of GC376 (0, 0.5, 1, 2, 4, 6, 8, 10 μM), GS441524 (0, 0.5, 1, 2, 4, 6, 8, 10 μM) and GC376+GS441524 (0, 0.25, 0.5, 1, 2, 3, 4, 5 μM) or with vehicle solution (12% sulfobutylether-β-cyclodextrin, pH 3.5) alone for 1 h. The cells were then infected with HRB26 or HRB26M at an MOI of 0.005 and incubated for 1 h at 37°C. The cells were washed with PBS, and virus growth medium containing the indicated amounts of GC376, GS441524 and GC376+GS441524 or vehicle solution alone was added. The supernatants were collected at 24 h p.i. for viral titration by a PFU assay in Vero E6 cells. Relative viral titers were calculated on the basis of the ratios to the viral titers in the mock-treated counterparts. The data were analyzed using GraphPad Prism 7.0. The results are shown as the mean values with standard deviations of three independent experiments.

In vivo toxicity study of GC376 and GS441524

The toxicity studies were performed in 4- to 6-week-old female BALB/c mice. BALB/c mice were assigned to four groups (five mice per group), one mock group (i.m. administration of solvent) and three i.m. administered groups: GC376 (40 mM/l, 100 μl), GS441524 (40 mM/l, 100 μl) and GC376+GS441524 (20 mM/l, 100 μl), respectively. Mice in the mock and experimental groups were weighed daily for 15 days. In addition, blood samples were collected at 0, 5, 10 and 15 days after administration. Various blood chemistry values or blood cell counts were performed at Wuhan Servicebio Biological Technology Co., Ltd. The data were analyzed using GraphPad Prism 7.0.

In vivo antiviral study of GC376 and GS441524

Firstly, groups of six 4- to 6-week-old female mice were treated i.m. with a loading dose of GC376 (40 or 8 mM/l, 100 μl), GS441524 (40 or 8 mM/l, 100 μl) and GC376+GS441524 (20 or 4 mM/l, 100 μl), followed by a daily maintenance dose. Alternatively, mice were treated intranasally with a single treatment (GC376, 20 mM/l, 50 μl; GS441524, 20 mM/l, 50 μl; GC376+GS441524, 10 mM/l, 50 μl) or a combination of GC376 (20 mM/l, 50 μl, i.n. and 40 mM/l, 100 μl, i.m.), GS441524 (20 mM/l, 50 μl, i.n. and 40 mM/l, 100 μl, i.m.) and GC376+GS441524 (10 mM/l, 50μl, i.n. and 20 mM/l, 100 μl, i.m.), followed by a daily maintenance dose. As a control, mice were administered vehicle solution (12% sulfobutylether-β-cyclodextrin, pH 3.5) daily. One hour after administration of the loading dose of GC376, GS441524 and GC376+GS441524 or vehicle solution, each mouse was inoculated intranasally with103.6 PFU of HRB26M in 50 μl. Three mice from each group were euthanized on days 3 and 5 p.i. The nasal turbinates and lungs were collected for viral detection by qPCR and PFU assay according to previously described methods (4, 30). The amount of vRNA for the target SARS-CoV-2 N gene was normalized to the standard curve from a plasmid (pBluescript II SK-N, 4,221 bp) containing the full-length cDNA of the SARS-CoV-2 N gene. The assay sensitivity was 1000 copies/ml. The data were analyzed using Microsoft Excel 2016 and GraphPad Prism 7.0.

Pharmacokinetics study of GC376 and GS441524 in SD rats

Five healthy SPF SD rats of 4-6 weeks were used in a single-dose PK study. At time point zero, the SD rats of groups A, B and C received i.m. injections of GC376 (111 mg/kg), GS441524 (67 mg/kg) and GC376+GS441524 (55.5+33.5 mg/kg), which are the same doses used in mice according to weight. Approximately 200μl of blood was collected at 0, 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h from the tail vein and placed in a precooled polypropylene centrifuge tube containing 3.0 μl of 40% EDTAK2. Then, the whole blood was centrifuged at 7800 g/min for 10 min at 4℃. Plasma was collected and stored in a freezer at −80°C. Plasma drug concentration was analyzed using LC-MS/MS. Pharmacokinetic parameters were calculated using WinNonlin software (version 6.4), and a non-atrioventricular model was used for data fitting. The data were analyzed using Microsoft Excel 2016 and GraphPad Prism 7.0.

Ethics statement, biosafety and facility

All of the mice used in this study were maintained in compliance with the recommendations in the Regulations for the Administration of Affairs Concerning Experimental Animals made by the Ministry of Science and Technology of China. The toxicity studies in mice and single-dose PK study in SD rats were performed using protocols that were approved by the Scientific Ethics Committee of Huazhong Agricultural University. All experiments with infectious SARS-CoV-2 were performed in the biosafety level 4 and animal biosafety level 4 facilities in the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS), which are approved for this use by the Ministry of Agriculture and Rural Affairs of China.

Statistical analysis

Statistical analysis was carried out using GraphPad Prism 7.0. Statistical significance was determined using an unpaired two-tailed Student’s t test. Data are presented as mean values +/− SD (95% confidence interval). *, P <0.05 was considered statistically significant; **, P < 0.01 was considered highly significant; ***, P < 0.001 and ****, P < 0.0001 were considered extremely significant. All experiments were further confirmed using biological repeats.

Data availability

Coordinates and structural factors for SARS-CoV-2 Mpro in complex with GC376 were deposited in the Protein Data Bank with accession number 7CBT. Other data supporting the findings of this study are available within the paper and its Supplementary Information files, or upon reasonable request from the corresponding author.

Author contributions

G.Q.P., Z.G.B., Z.F.F. and H.C.C. designed the study; Y.J.S., L.S., Z.Y.W., C.W., Y.Y.Y, Z.J. and F.L.G. performed the experiments; G.Q.P. and Z.G.B. oversaw the project; Y.J.S., L.S., Z.F.F., H.C.C., Z.G.B and G.Q.P. analyzed the data and wrote the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to G.Q.P. or Z.G.B..

Acknowledgments

We thank research associates at the Center for Protein Research (CPR), Huazhong Agricultural University, for technical support. We also thank Professor Sheng-ce Tao from Shanghai Jiao Tong University for providing SARS-CoV-2 Mpro plasmid. This work was supported by National Natural Science Foundation of China Grants 31722056, the National Key R&D Program of China (Grant No. 2018YFC1200601), the Natural Science Foundation of Hubei Province of China (Grant No.2020FCA040), the Fundamental Research Funds for the Central Universities (Grant No.2662020PY001) and the Applied Technology Research and Development Project of Heilongjiang Province, China (Grant No. GA20C006).

References

  1. 1.↵
    Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. 2020. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369:77–81.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, Avanzato VA, Bushmaker T, Flaxman A, Ulaszewska M, Feldmann F, Allen ER, Sharpe H, Schulz J, Holbrook M, Okumura A, Meade-White K, Pérez-Pérez L, Edwards NJ, Wright D, Bissett C, Gilbride C, Williamson BN, Rosenke R, Long D, Ishwarbhai A, Kailath R, Rose L, Morris S, Powers C, Lovaglio J, Hanley PW, Scott D, Saturday G, de Wit E, Gilbert SC, Munster VJ. 2020. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature doi:10.1038/s41586-020-2608-y.
    OpenUrlCrossRefPubMed
  3. 3.
    Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, Martinez DR, Loos C, Atyeo C, Fischinger S, Burke JS, Slein MD, Chen Y, Zuiani A, Lelis FJN, Travers M, Habibi S, Pessaint L, Van Ry A, Blade K, Brown R, Cook A, Finneyfrock B, Dodson A, Teow E, Velasco J, Zahn R, Wegmann F, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kirilova M, Kordana N, Lin Z, Maxfield LF, Nampanya F, Nityanandam R, Ventura JD, Wan H, Cai Y, Chen B, Schmidt AG, Wesemann DR, Baric RS, et al. 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369:806–811.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, Wang B, Zhao Z, Song X, Chen Y, Liu R, Fu L, Zhang J, Guo Q, Wang C, Yang Y, Fang T, Lv P, Wang J, Xu J, Li J, Yu C, Hou L, Bu Z, Chen W. 2020. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 11:4081.
    OpenUrl
  5. 5.
    Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. 2020. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395:1845–1854.
    OpenUrlCrossRef
  6. 6.↵
    Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396:479–488.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. 2006. Nidovirales: evolving the largest RNA virus genome. Virus Res 117:17–37.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Perlman S, Netland J. 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 7:439–50.
    OpenUrlCrossRefPubMed
  9. 9.↵
    de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. 2018. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol 419:1–42.
    OpenUrlCrossRef
  10. 10.↵
    Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie YC, Tian G, Jiang HW, Tao SC, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE. 2020. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 368:1499–1504.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Ye G, Wang X, Tong X, Shi Y, Fu ZF, Peng G. 2020. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376. Viruses 12.
  12. 12.↵
    Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Wang J. 2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30:678–692.
    OpenUrl
  13. 13.↵
    Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P, Song H, Shi Y, Li X, Tan W, Qi J, Gao GF. 2020. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11:4417.
    OpenUrl
  14. 14.↵
    Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang KO. 2012. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 86:11754–62.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Tiew KC, He G, Aravapalli S, Mandadapu SR, Gunnam MR, Alliston KR, Lushington GH, Kim Y, Chang KO, Groutas WC. 2011. Design, synthesis, and evaluation of inhibitors of Norwalk virus 3C protease. Bioorg Med Chem Lett 21:5315–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Vuong W, Khan MB, Fischer C, Arutyunova E, Lamer T, Shields J, Saffran HA, McKay RT, van Belkum MJ, Joyce MA, Young HS, Tyrrell DL, Vederas JC, Lemieux MJ. 2020. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun 11:4282.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Mandadapu SR, Weerawarna PM, Gunnam MR, Alliston KR, Lushington GH, Kim Y, Chang KO, Groutas WC. 2012. Potent inhibition of norovirus 3CL protease by peptidyl α-ketoamides and α-ketoheterocycles. Bioorg Med Chem Lett 22:4820–6.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC. 2016. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog 12:e1005531.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR. 2018. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio 9.
  20. 20.
    Cho A, Saunders OL, Butler T, Zhang L, Xu J, Vela JE, Feng JY, Ray AS, Kim CU. 2012. Synthesis and antiviral activity of a series of 1’-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett 22:2705–7.
    OpenUrlCrossRefPubMed
  21. 21.
    Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9.
  22. 22.↵
    Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381–5.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Choy KT, Wong AY, Kaewpreedee P, Sia SF, Chen D, Hui KPY, Chu DKW, Chan MCW, Cheung PP, Huang X, Peiris M, Yen HL. 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 178:104786.
    OpenUrlPubMed
  24. 24.
    Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271.
    OpenUrlCrossRefPubMed
  25. 25.
    Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S, Chufang L, Jin Z, Zhenhua J, Haiming J, Kui Z, Shuxiang H, Jun D, Xiaobo L, Xiaotao H, Lin W, Nanshan Z, Zifeng Y. 2020. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 156:104761.
    OpenUrl
  26. 26.
    Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. 2020. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222.
    OpenUrlCrossRefPubMed
  27. 27.↵
    de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 117:6771–6776.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    Yan VC, Muller FL. 2020. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. ACS Med Chem Lett 11:1361–1366.
    OpenUrlCrossRef
  29. 29.↵
    Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastri E, D’Avolio A, Ippolito G, Agrati C. 2020. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother 75:2977–2980.
    OpenUrl
  30. 30.↵
    Wang J, Shuai L, Wang C, Liu R, He X, Zhang X, Sun Z, Shan D, Ge J, Wang X, Hua R, Zhong G, Wen Z, Bu Z. 2020. Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell doi:10.1007/s13238-020-00767-x:1-7.
    OpenUrlCrossRef
  31. 31.↵
    Pedersen NC, Kim Y, Liu H, Galasiti Kankanamalage AC, Eckstrand C, Groutas WC, Bannasch M, Meadows JM, Chang KO. 2018. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg 20:378–392.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Kim Y, Shivanna V, Narayanan S, Prior AM, Weerasekara S, Hua DH, Kankanamalage AC, Groutas WC, Chang KO. 2015. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J Virol 89:4942–50.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    Perera KD, Galasiti Kankanamalage AC, Rathnayake AD, Honeyfield A, Groutas W, Chang KO, Kim Y. 2018. Protease inhibitors broadly effective against feline, ferret and mink coronaviruses. Antiviral Res 160:79–86.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH, 3rd., Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP. 2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep 32:107940.
    OpenUrlCrossRefPubMed
  35. 35.↵
    Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, Liepnieks M, Pedersen NC. 2018. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol 219:226–233.
    OpenUrlCrossRef
  36. 36.↵
    Tchesnokov EP, Feng JY, Porter DP, Götte M. 2019. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses 11.
  37. 37.↵
    Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295:6785–6797.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Shi Y, Li Y, Lei Y, Ye G, Shen Z, Sun L, Luo R, Wang D, Fu ZF, Xiao S, Peng G. 2016. A Dimerization-Dependent Mechanism Drives the Endoribonuclease Function of Porcine Reproductive and Respiratory Syndrome Virus nsp11. J Virol 90:4579–4592.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    Shi Y, Tong X, Ye G, Xiu R, Li L, Sun L, Shi J, Li M, Song Y, Fan C, Shi K, Fu ZF, Xiao S, Peng G. 2020. Structural Characterization of the Helicase nsp10 Encoded by Porcine Reproductive and Respiratory Syndrome Virus. J Virol 94.
  40. 40.↵
    Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. 2006. HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr 62:859–66.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. 2002. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58:1948–54.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126–32.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    Laskowski RA, Swindells MB. 2011. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51:2778–86.
    OpenUrlCrossRefPubMed
Back to top
Posted November 13, 2020.
Download PDF
Email
The Preclinical Inhibitor GS441524 in Combination with GC376 Efficaciously Inhibited the Proliferation of SARS-CoV-2 in the Mouse Respiratory Tract
Yuejun Shi, Lei Shuai, Zhiyuan Wen, Chong Wang, Yuanyuan Yan, Zhe Jiao, Fenglin Guo, Zhen F. Fu, Huanchun Chen, Zhigao Bu, Guiqing Peng
bioRxiv 2020.11.12.380931; doi: https://doi.org/10.1101/2020.11.12.380931
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area